Inpatient Monitoring and Prognostic Importance of B-Type Natriuretic Peptide

Congestive Heart Failure

Volumn 14, Issue 4, 2008, Pages 30-34

  Aspromonte, Nadia ^a   Valle, Roberto ^b   Peacock, William F ^c   Vanderheyden, Marc ^d   Maisel, Alan ^e  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b Ospedale Civile   (Italy)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CARDIOVASCULAR CENTER   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT;

HEART FAILURE; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; STATISTICS;

HEART FAILURE; HOSPITALIZATION; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK ASSESSMENT;

EID: 55249090694     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.08214.x     Document Type: Review

References (31)

1. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76-84.
2. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464-474.
3. Peacock WF IV, Young J, Collins S, et al. Heart failure observation units: optimizing care. Ann Emerg Med. 2006;47(1):22-33.
4. Di Lenarda A, Scherillo M, Maggioni AP, et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds. The TEMISTOCLE study. Am Heart J. 2003;146:E12.
5. Maisel A, Hollander JE, Guss D, et al. Primary results of the rapid emergency department heart failure outpatient trial (REDHOT). J Am Coll Cardiol. 2004;44:1328-1333.
6. Januzzi JL Jr, van Kimmenade RRJ, Lainchbury JG, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute congestive heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP (ICON) study. Eur Heart J. 2006;27:330-337.
7. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
8. Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol. 1997;273:H2678-H2686.
9. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21-29.
10. Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290(1):H17-H29.
11. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiogra-phy and tissue Doppler imaging in the estimation of left ventricular filling How to diagnose diastolic heart failure pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-1794.
12. Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation. 2004;109:2432-2439.
13. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174.
14. Cournot M, Leprince P, Destrac S, et al. Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am J Geriatr Cardiol. 2007;16(1):8-14.
15. Valle R, Aspromonte N, Giovinazzo P, et al. B-Type natriuretic peptide guided treatment for predicting outcome in patients hospitalized in subintensive care unit with acute heart failure. J Card Fail. 2008;14(3):219-224.
16. Doust JA, Pietrzak E, Dobson AJ, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: a systematic review. BMJ. 2005;330:625-634.
17. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941.
18. Cheng V, Kazanegra R, Garcia A, et al. A rapid bedside test for B-Type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
19. Bettencourt P, Frioes F, Azevedo A, et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol. 2004;93:45-48.
20. Fonarow GC, Peacock WF, Phillips CO, et al; ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943-1950.
21. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
22. Aspromonte N, Milli M, Scardovi AB, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure: The BIC study. Eur Heart J. 2006;27(Abstract suppl):14-15.
23. Andersson B, Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail. 2000;6:208-213.
24. Kirk V, Bay M, Parner J, et al. N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study. Eur J Heart Fail. 2004;6:335-341.
25. Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005;11(7):498-503.
26. Aspromonte N, Feola M, Milli M, et al. Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Diabet Med. 2007;24(2):124-130.
27. Valle R, Prevaldi C, D'Eri A, et al. B-type natriuretic peptide predicts postdischarge prognosis in elderly patients admitted due to cardiogenic pulmonary edema. Am J Geriatr Cardiol. 2006;15(4):202-207.
28. Ledwidge M, Ryan E, O'Loughlin C, et al. Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. Eur J Heart Fail. 2005;7:385-391.
29. Valle R, Aspromonte N, Carbonieri E, et al. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol. 2008;126:400-406.
30. DeBusk RF, Miller NH, Parker KM, et al. Care management for low risk patients with heart failure: a randomized, controlled trial. Ann Intern Med. 2004;141:606-613.
31. Aspromonte N, Canali C, Carbonieri E, et al. Low readmission rate of low B-type natriuretic peptide patients admitted for heart failure are not further reduced by an active cardiological follow-up. Eur J Heart Fail. 2005;4(suppl 1):43.